Skip to main content
. 2020 Jul 6;8(3):362. doi: 10.3390/vaccines8030362

Figure 1.

Figure 1

Adjusted vaccine effectiveness against pooled HPV 16/18 and HPV 31/45/52. Whereas the HPV types 16/18 infection rate among the vaccinated group was 0.1%, the infection rate among the unvaccinated group was 2.2%, which indicated a high vaccine effectiveness in the group of women vaccinated before their first intercourse (93.9%). The prevalence of cross-protected types of HPV 31/45/52 was also significantly lower in the vaccinated group where the vaccine effectiveness was 67.7% [6].